drugset / Trial / NCT04923269

A Study of LY3532226 in Healthy Participants

NCT04923269

Phase 1 Completed 41 enrolled Eli Lilly and Company
RandomizedParallel-groupDouble-blindBasic science

Summary

The main purpose of this study is to evaluate the safety and tolerability of the study drug known as LY3532226 in healthy participants. Blood tests will be performed to check how much LY3532226 gets into the bloodstream and how long it takes the body to eliminate it. This study will last approximately 8 weeks including screening period.

Timeline

Start
2021-06-10
Primary completion
2021-10-28
Completion
2021-10-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Macupatide Protein / enzyme biologic Subcutaneous

Indications

No indication recorded.